Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
LIPOSYN 20% is an intravenous lipid emulsion approved in 1981 by Abbott for parenteral nutrition support. The product supplies essential fatty acids and calories to patients unable to consume nutrition orally or enterally. It functions as a metabolic substrate in total parenteral nutrition (TPN) formulations.
Approaching loss of exclusivity with low competitive pressure (30%) signals consolidation phase; expect smaller commercial teams and focus on operational efficiency and hospital channel management.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Roles linked to LIPOSYN 20% are primarily in hospital channel management, nutritional product marketing, and regulatory compliance rather than innovative development. Career growth on this product is constrained by mature market position and approaching LOE, making it suitable for professionals seeking stable, operationally-focused roles rather than high-growth trajectories.
Worked on LIPOSYN 20% at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.